Heparin-Like Anticoagulant: First Case Described in a Metastatic Biliopancreatic Cancer
Rosana Raimondi,Sofia Aguirre,Valeria Monserrat,Silvina Pons,Damian Contardo,Alejandra Scazziota
DOI: https://doi.org/10.1055/s-0044-1788734
2024-07-26
Seminars in Thrombosis and Hemostasis
Abstract:The development of acquired heparin-like anticoagulants in vivo is an extremely rare condition that has been associated with hematological malignancies and other neoplastic processes such as bladder, breast, and hepatocellular carcinoma.[1] We report here the finding of a heparin-like anticoagulant in a young patient diagnosed with metastatic biliopancreatic adenocarcinoma. A 45-year-old male with a previous history of alcoholism and smoking of 66 packs-years was admitted to hospital due to dyspnea on effort and inability to move his left arm. Patient referred weight loss of 30 kg and occasional nausea, vomiting, and night sweats that evolved over several months. Initial laboratory tests showed thrombocytopenia (platelet count 19 × 10 9 /L) and severe anemia (hemoglobin 5.2 g/dL), which required transfusion of 2 units of red blood cells. No bleeding was reported. A chest computed tomography reported cervical lymphadenopathy, mediastinal and axillar masses generating functional impairment of the left arm. A lymphoproliferative syndrome was suspected. Flow cytometry and bone marrow smear showed no evidence of oncohematological disease. No bruising was reported as a result of the bone marrow examination. However, a massive infiltration of nonhematological malignant tumor cells in the bone marrow was observed. The patient also underwent a surgical procedure of a cervical lymph node biopsy without any hemostatic complications. Initial laboratory assessment of hemostasis revealed a prolonged activated partial thromboplastin time (aPTT) of 67 seconds, a prothrombin time (PT) of 67%, an international normalized ratio of 1.31, and a normal fibrinogen level ([Table 1]). The aPTT did not correct with a 1:1 mix with normal pooled plasma (NPP). Thrombin time (TT) was extremely prolonged and reptilase time was normal. Anti-Xa activity was assessed and established the presence of heparin-like activity with a result of 0.30 IU/mL. As it was confirmed that the patient was not receiving heparin by any route of administration and preanalytical errors were excluded (including heparin contamination), the presence of a circulating heparin-like anticoagulant was suspected. Patient Reference interval PT 67 70–110% INR 1.31 0.94–1.27 aPTT 67 30–43 s aPTT, ratio 1.84 0.82–1.18 Fibrinogen 3.21 2–4 g/L Thrombin time 156 24–28 s Reptilase time 19 17–21 s Anti-Xa activity 0.30 300 >300 0.45 25.5 153.1 0.60 26.1 119.8 2.50 23.1 32.1 4.50 23.5 26.4 a Testing performed on second sample collected 3 days after admission. Addition of heparanase (Dade Hepzyme, Siemens) to 0.5 mL of patient plasma caused a shortening of both TT and aPTT and a complete neutralization of anti-Xa activity ([Table 3]). Before After Reference interval Thrombin time >300 33 24–28 s aPTT 115 54 30–43 s aPTT, ratio 3.15 1.48 0.82–1.18 Anti-Xa activity 0.44 <0.10 <0.10 IU/mL Abbreviation: aPTT, activated partial thromboplastin time. a Testing performed on second sample collected 3 days after admission. Twelve days after admission, the patient developed hematomas on both arms and left flank. There was no evidence of an intra or retroperitoneal bleeding that could have explained a Grey-Turner's sign. No specific therapy was implemented, and palliative care was established due to a terminal prognosis. The patient died of cardiopulmonary arrest 3 days later. Autopsy revealed a poorly differentiated biliopancreatic ductal adenocarcinoma (PDAC) with multiple angiolymphatic embolism, ganglionar involvement, and bone marrow, pleural, gastric and pulmonary metastases. Heparin-like anticoagulants have been previously described, typically associated with hematological malignancies, such as multiple myeloma, systemic mastocytosis, and chronic lymphoid leukemia, and other situations like asthma, systemic candidiasis, and pregnancy.[ -Abstract Truncated-
peripheral vascular disease,hematology